FDA re­names and re­struc­tures on­col­o­gy of­fice

The FDA’s of­fice re­spon­si­ble for ap­prov­ing can­cer ther­a­pies has been re­named the Of­fice of On­co­log­ic Dis­eases (OOD) and re­struc­tured to add new di­vi­sions, the agency an­nounced Wednes­day.

OOD, which was pre­vi­ous­ly known as the Of­fice of Hema­tol­ogy and On­col­o­gy Prod­ucts (OHOP), will shift from three clin­i­cal di­vi­sions and one non­clin­i­cal di­vi­sion to six di­vi­sions, in­clud­ing three di­vi­sions of on­col­o­gy:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.